Skip to main content
Clinical Trials/NCT05615545
NCT05615545
Recruiting
Not Applicable

Safety and Efficacy of Cryoablation in the Treatment of Advanced Bone and Soft Tissue Tumors: a Single-center Retrospective Study

Henan Cancer Hospital1 site in 1 country30 target enrollmentMarch 10, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sarcoma
Sponsor
Henan Cancer Hospital
Enrollment
30
Locations
1
Primary Endpoint
Survival rates
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This is a single-center, open, retrospective clinical study of patients with metastatic/surgically unresectable bone and soft tissue sarcoma undergoing cryoablation of selected tumor lesions. All eligible patients were enrolled. Basic data and treatment methods of these patients were collected, and efficacy and safety were evaluated.

Detailed Description

This is a single-center, open, retrospective clinical study of patients with metastatic/surgically unresectable bone and soft tissue sarcoma undergoing cryoablation of selected tumor lesions. Clinical data of eligible patients were scheduled to be retrospectively collected from December 2016 to February 28, 2022. All patients eligible for inclusion. Basic data and treatment methods of these patients were collected, and efficacy and safety were evaluated.

Registry
clinicaltrials.gov
Start Date
March 10, 2022
End Date
October 28, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Wang Jiaqiang

associate chief physician

Henan Cancer Hospital

Eligibility Criteria

Inclusion Criteria

  • No age restriction, male or female.
  • The pathological diagnosis was a subtype of bone and soft tissue sarcoma.
  • The clinical stage was determined to be metastatic or locally unresectable bone and soft tissue sarcoma.
  • At least one cryoablation of tumor lesions was performed in our hospital.
  • Target lesions can be evaluated according to the efficacy evaluation criteria for solid tumors (RECIST; Version 1.1) Measure diameter changes.
  • Follow-up data were complete.

Exclusion Criteria

  • Not applicable.

Outcomes

Primary Outcomes

Survival rates

Time Frame: 12 months after surgery

1-year survival rate

There was no local recurrence survival rate

Time Frame: 12 months after surgery

The 1-year survival rate without local recurrence

Study Sites (1)

Loading locations...

Similar Trials